While Arrowhead Pharmaceuticals Inc has overperformed by 3.80%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARWR fell by -2.66%, with highs and lows ranging from $30.41 to $9.57, whereas the simple moving average jumped by 3.04% in the last 200 days.
On June 05, 2024, Goldman started tracking Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) recommending Neutral. A report published by BofA Securities on December 04, 2023, Initiated its previous ‘Buy’ rating for ARWR. Citigroup also rated ARWR shares as ‘Neutral’, setting a target price of $33 on the company’s shares in an initiating report dated September 19, 2023. SVB Securities May 12, 2023d its ‘Outperform’ rating to ‘Market Perform’ for ARWR, as published in its report on May 12, 2023. SMBC Nikko’s report from April 26, 2023 suggests a price prediction of $80 for ARWR shares, giving the stock a ‘Outperform’ rating. SVB Securities also rated the stock as ‘Outperform’.
Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Arrowhead Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -24.67% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.15, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and ARWR is recording an average volume of 1.70M. On a monthly basis, the volatility of the stock is set at 4.97%, whereas on a weekly basis, it is put at 4.64%, with a loss of -3.07% over the past seven days. Furthermore, long-term investors anticipate a median target price of $41.77, showing growth from the present price of $18.3, which can serve as yet another indication of whether ARWR is worth investing in or should be passed over.
How Do You Analyze Arrowhead Pharmaceuticals Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 16.58%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 74.56% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ARWR shares are owned by institutional investors to the tune of 74.56% at present.
